$2.25 Billion is the total value of Novo Holdings A/S's 54 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYT | New | CYTEIR THERAPEUTICS INC | $103,585,000 | – | 4,840,413 | +100.0% | 4.60% | – |
| VERV | New | VERVE THERAPEUTICS INC | $47,794,000 | – | 793,265 | +100.0% | 2.12% | – |
| VECT | New | VECTIVBIO HLDG AG | $41,067,000 | – | 3,522,019 | +100.0% | 1.82% | – |
| RPHM | New | RENEO PHARMACEUTICALS INC | $32,005,000 | – | 3,430,377 | +100.0% | 1.42% | – |
| TMCI | New | TREACE MED CONCEPTS INC | $10,097,000 | – | 323,000 | +100.0% | 0.45% | – |
| ABCL | New | ABCELLERA BIOLOGICS INC | $9,292,000 | – | 422,382 | +100.0% | 0.41% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $5,879,000 | – | 34,679 | +100.0% | 0.26% | – |
| BAMR | New | BROOKFIELD ASSET MGMT REINScl a exch lt vtg | $1,102,000 | – | 21,179 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.